Intellia Therapeutics Inc
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.

Postmarket

Last Trade
Delayed
$42.98
Change Since Close

Change Since Close

Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.

0.54 (1.27%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$42.44
Day's Change
2.32 (5.78%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
42.69
Day's Low
40.27
Volume
(Below Average)
Volume:
1,042,423

10-day average volume:
1,256,801
1,042,423
Historical quotes & splits

Shake Shack stock climbs on narrowing third-quarter loss, revenue beat

7:32 am ET November 3, 2022 (MarketWatch)
Print

Shake Shack Inc.'s stock climbed 5.9% Thursday before market open, lifted by a narrowing third-quarter loss and revenue that just topped analysts' estimate. The restaurant chain reported a third-quarter loss of $2 million, or 5 cents a share, compared with a loss of $2.2 million, or 6 cents a share, in the same period last year. On an adjusted basis, Shake Shack reported a loss of 6 cents a share. Analysts surveyed by FactSet had forecast a loss of 6 cents a share. The company's third-quarter revenue was $227.8 million, compared with $193.9 million in the year-ago quarter and just above FactSet consensus of $225.9 million. Shake Shack's same-store sales rose 6.3% from the prior-year's quarter, above the FactSet consensus of 5.4%.

-James Rogers

(END) Dow Jones Newswires

November 03, 2022 07:32 ET (11:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.

3rd Party Research Disclosure